Home > News content

The U.S. denies that Germany wants to "buy out" Germany's new crown vaccine

via:新华社     time:2020/3/16 17:22:02     readed:149

Germany's government promised on the 15th to stop the u. s ." buyout "of a new coronavirus vaccine is being developed in germany. There are reports that US President Donald Trump has proposed a "exclusive right" to buy the results of the business.Germany's economy minister, peter altmeer, told a german television on the same day :" germany, do n' t sell in response to the sunday world newspaper front page related reports. The report is entitled Trump to Berlin.

(original title: US wants to "buy out" Germany's new crown vaccine rejected)

Lu Ai Hua

1600px-Frauenkirche_Munich_-_View_from_Peterskirche_Tower2.jpg

Data map

"Exclusive rights"

Trump is trying to get "exclusive rights" for a new coronavirus vaccine being developed by German company "cure" vaccine company, the report said. The newspaper previously quoted people close to the German government as the source, saying trump offered $1 billion to seek the vaccine technology "for the exclusive use of the United States.".

Reuters quoted similar sources as saying that the United States is considering how to acquire the technology and attract the German company to the United States on the condition of funds. Germany is taking countermeasures against monopoly of vaccine technology by any country.

German Interior Minister Horst Zehofer spoke about the report at a news conference on the 16th :" I can only say that I heard about it several times today from German officials, and we will discuss it in tomorrow's crisis management committee ."

"Novel coronavirus vaccine and active substances have been successfully developed in Germany and Europe," a spokeswoman for the German Ministry of Health said. In this regard, the government is in-depth communication with "cure" vaccine companies. "

Urgent clarification

Richard Greene, the US ambassador to Germany, tweeted that the newspaper was wrong.

A U.S. official Friday identified the report as "grossly exaggerated" and denied that the United States was seeking to "take possession" of potential vaccines.

"The U.S. government has reached out to a number of businesses (more than 25) that claim to be able to assist in vaccine development, most of which have received seed money from U.S. investors," the official said. "We will continue to talk to any business that claims to be able to help, and any solution will be shared globally."

The newspaper's report triggered a "denunciation" by German politicians. "International cooperation is important now, not a national self-interest ," said Erwin Rudder, member of the German Parliamentary Committee on Health.

Christian Lindner, leader of Germany's Liberal Democratic Party, identified Trump as "election speculation ", meaning to canvass. "It is clear that Trump will do everything in his campaign ."

Issue statement

The main character of the storm "cured" vaccine company 15 voice, denied the relevant rumors. Ditmar Hopper, the company's leading investor, said it had no intention of selling and hoped it would develop vaccines.

Germany's economy minister, artmeyer, welcomed the "wise decision" to make it clear that the government has the right to review foreign M & A. "When it comes to critical infrastructure and national and European interests, we will act if necessary."

According to German foreign trade law, the German government can review acquisition requests from non EU countries "if national or European security interests are threatened".

"Recovery" vaccine company was founded in 2000, with its headquarters in Thuringia, Germany. It has branches in Frankfurt and Boston. It is located in "cancer treatment, antibody based treatment, rare disease treatment and preventive vaccine development". Its laboratory cooperates with Paul Ehrlich Institute under the German Ministry of health.

Last week, the company was quirky, with Dietmar Hope replacing Daniel Menichella as chief executive. The latter was invited in early March to meet with Trump's deputy, Mike Burns, and representatives of several pharmaceutical companies at the White House.

"We are very confident that we will be able to develop an effective vaccine candidate in a few months," menichella was quoted on the company's website as saying after the meeting

China IT News APP

Download China IT News APP

Please rate this news

The average score will be displayed after you score.

Post comment

Do not see clearly? Click for a new code.

User comments